Massive CFD simulation datasets can be distilled into compact reduced-order surrogate models of just a few megabytes using machine learning. Rather than sifting through overwhelming data files, the model interpolates between simulated test points to predict key bioreactor parameters—including kLa, shear rate distribution, and mixing times—in milliseconds for any given operating condition.
Conventional scale-up rules of thumb, such as constant power per volume, fail to accurately reproduce cellular microenvironments when working with shear-sensitive cell therapies or delicate organisms like Streptomyces. By simulating and matching comprehensive physical parameters across vessels using CFD, teams achieve far more comparable cell morphology and reliable cell growth without relying on protective additives like antifoam.
Scaling from shake flasks to stirred-tank reactors is notoriously difficult because flasks feature violent surface rotation and thin liquid wall films. The free-surface algorithms originally developed to track large rising gas bubbles in 160,000-liter reactors can accurately model oxygen transfer and shear in shake flasks, allowing direct mathematical translation into stirred-tank aeration and agitation parameters.
When deviations or disturbances occur in continuous bioprocessing, determining the exact volume of impacted material downstream is difficult. Through first-principle CFD and rapid response models across stirred tanks, connectors, filters, and chromatography units, teams can simulate the whole residence time distribution chain to pinpoint precisely which product must be discarded and which can be retained safely.
Regulators welcome validated CFD data because it replaces unnecessary wet experiments and wasted process media. While the manufacturing-focused ASME V&V 80 standard is still being drafted, drug developers can already submit manufacturing CFD models to the FDA by applying the existing ASME V&V 40 medical device standard's credibility assessment framework.
Instead of waiting for physical tech transfer runs, biotech startups can use CFD to determine whether a process refined in micro-bioreactors will run safely in a CDMO's specific reactor fleet. Performing this virtual scale-up in advance derisks facility selection, reduces timeline and financial commitments, and provides verifiable technical proof for prospective investors.
